These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 31348886)

  • 61. Broadly neutralizing antibodies against HIV-1: templates for a vaccine.
    van Gils MJ; Sanders RW
    Virology; 2013 Jan; 435(1):46-56. PubMed ID: 23217615
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Structural Constraints at the Trimer Apex Stabilize the HIV-1 Envelope in a Closed, Antibody-Protected Conformation.
    Guzzo C; Zhang P; Liu Q; Kwon AL; Uddin F; Wells AI; Schmeisser H; Cimbro R; Huang J; Doria-Rose N; Schmidt SD; Dolan MA; Connors M; Mascola JR; Lusso P
    mBio; 2018 Dec; 9(6):. PubMed ID: 30538178
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Characterization and Implementation of a Diverse Simian Immunodeficiency Virus SIVsm Envelope Panel in the Assessment of Neutralizing Antibody Breadth Elicited in Rhesus Macaques by Multimodal Vaccines Expressing the SIVmac239 Envelope.
    Kilgore KM; Murphy MK; Burton SL; Wetzel KS; Smith SA; Xiao P; Reddy S; Francella N; Sodora DL; Silvestri G; Cole KS; Villinger F; Robinson JE; Pulendran B; Hunter E; Collman RG; Amara RR; Derdeyn CA
    J Virol; 2015 Aug; 89(16):8130-51. PubMed ID: 26018167
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Challenges for structure-based HIV vaccine design.
    Schief WR; Ban YE; Stamatatos L
    Curr Opin HIV AIDS; 2009 Sep; 4(5):431-40. PubMed ID: 20048708
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Live rubella vectors can express native HIV envelope glycoproteins targeted by broadly neutralizing antibodies and prime the immune response to an envelope protein boost.
    Virnik K; Nesti E; Dail C; Scanlan A; Medvedev A; Vassell R; McGuire AT; Stamatatos L; Berkower I
    Vaccine; 2018 Aug; 36(34):5166-5172. PubMed ID: 30037665
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Changes in Structure and Antigenicity of HIV-1 Env Trimers Resulting from Removal of a Conserved CD4 Binding Site-Proximal Glycan.
    Liang Y; Guttman M; Williams JA; Verkerke H; Alvarado D; Hu SL; Lee KK
    J Virol; 2016 Oct; 90(20):9224-36. PubMed ID: 27489265
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates.
    Saunders KO; Nicely NI; Wiehe K; Bonsignori M; Meyerhoff RR; Parks R; Walkowicz WE; Aussedat B; Wu NR; Cai F; Vohra Y; Park PK; Eaton A; Go EP; Sutherland LL; Scearce RM; Barouch DH; Zhang R; Von Holle T; Overman RG; Anasti K; Sanders RW; Moody MA; Kepler TB; Korber B; Desaire H; Santra S; Letvin NL; Nabel GJ; Montefiori DC; Tomaras GD; Liao HX; Alam SM; Danishefsky SJ; Haynes BF
    Cell Rep; 2017 Feb; 18(9):2175-2188. PubMed ID: 28249163
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques.
    Klasse PJ; Ketas TJ; Cottrell CA; Ozorowski G; Debnath G; Camara D; Francomano E; Pugach P; Ringe RP; LaBranche CC; van Gils MJ; Bricault CA; Barouch DH; Crotty S; Silvestri G; Kasturi S; Pulendran B; Wilson IA; Montefiori DC; Sanders RW; Ward AB; Moore JP
    PLoS Pathog; 2018 Feb; 14(2):e1006913. PubMed ID: 29474444
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Induction of neutralizing antibodies in rhesus macaques using V3 mimotope peptides.
    Hessell AJ; McBurney S; Pandey S; Sutton W; Liu L; Li L; Totrov M; Zolla-Pazner S; Haigwood NL; Gorny MK
    Vaccine; 2016 May; 34(24):2713-21. PubMed ID: 27102818
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs.
    Li H; Zony C; Chen P; Chen BK
    J Virol; 2017 May; 91(9):. PubMed ID: 28148796
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Interdomain Stabilization Impairs CD4 Binding and Improves Immunogenicity of the HIV-1 Envelope Trimer.
    Zhang P; Gorman J; Geng H; Liu Q; Lin Y; Tsybovsky Y; Go EP; Dey B; Andine T; Kwon A; Patel M; Gururani D; Uddin F; Guzzo C; Cimbro R; Miao H; McKee K; Chuang GY; Martin L; Sironi F; Malnati MS; Desaire H; Berger EA; Mascola JR; Dolan MA; Kwong PD; Lusso P
    Cell Host Microbe; 2018 Jun; 23(6):832-844.e6. PubMed ID: 29902444
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies.
    Ahmed Y; Tian M; Gao Y
    AIDS Res Ther; 2017 Sep; 14(1):50. PubMed ID: 28893278
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Coadministration of CH31 Broadly Neutralizing Antibody Does Not Affect Development of Vaccine-Induced Anti-HIV-1 Envelope Antibody Responses in Infant Rhesus Macaques.
    Dennis M; Eudailey J; Pollara J; McMillan AS; Cronin KD; Saha PT; Curtis AD; Hudgens MG; Fouda GG; Ferrari G; Alam M; Van Rompay KKA; De Paris K; Permar S; Shen X
    J Virol; 2019 Mar; 93(5):. PubMed ID: 30541851
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells.
    Cohen YZ; Lorenzi JCC; Seaman MS; Nogueira L; Schoofs T; Krassnig L; Butler A; Millard K; Fitzsimons T; Daniell X; Dizon JP; Shimeliovich I; Montefiori DC; Caskey M; Nussenzweig MC
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237833
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques.
    Escolano A; Gristick HB; Abernathy ME; Merkenschlager J; Gautam R; Oliveira TY; Pai J; West AP; Barnes CO; Cohen AA; Wang H; Golijanin J; Yost D; Keeffe JR; Wang Z; Zhao P; Yao KH; Bauer J; Nogueira L; Gao H; Voll AV; Montefiori DC; Seaman MS; Gazumyan A; Silva M; McGuire AT; Stamatatos L; Irvine DJ; Wells L; Martin MA; Bjorkman PJ; Nussenzweig MC
    Nature; 2019 Jun; 570(7762):468-473. PubMed ID: 31142836
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Vaccine priming of rare HIV broadly neutralizing antibody precursors in nonhuman primates.
    Steichen JM; Phung I; Salcedo E; Ozorowski G; Willis JR; Baboo S; Liguori A; Cottrell CA; Torres JL; Madden PJ; Ma KM; Sutton HJ; Lee JH; Kalyuzhniy O; Allen JD; Rodriguez OL; Adachi Y; Mullen TM; Georgeson E; Kubitz M; Burns A; Barman S; Mopuri R; Metz A; Altheide TK; Diedrich JK; Saha S; Shields K; Schultze SE; Smith ML; Schiffner T; Burton DR; Watson CT; Bosinger SE; Crispin M; Yates JR; Paulson JC; Ward AB; Sok D; Crotty S; Schief WR
    Science; 2024 May; 384(6697):eadj8321. PubMed ID: 38753769
    [TBL] [Abstract][Full Text] [Related]  

  • 77. HIV Envelope Glycoform Heterogeneity and Localized Diversity Govern the Initiation and Maturation of a V2 Apex Broadly Neutralizing Antibody Lineage.
    Landais E; Murrell B; Briney B; Murrell S; Rantalainen K; Berndsen ZT; Ramos A; Wickramasinghe L; Smith ML; Eren K; de Val N; Wu M; Cappelletti A; Umotoy J; Lie Y; Wrin T; Algate P; Chan-Hui PY; Karita E; ; ; Ward AB; Wilson IA; Burton DR; Smith D; Pond SLK; Poignard P
    Immunity; 2017 Nov; 47(5):990-1003.e9. PubMed ID: 29166592
    [TBL] [Abstract][Full Text] [Related]  

  • 78. HIV-1 neutralizing antibodies elicited in humans by a prefusion-stabilized envelope trimer form a reproducible class targeting fusion peptide.
    Wang S; Matassoli F; Zhang B; Liu T; Shen CH; Bylund T; Johnston T; Henry AR; Teng IT; Tripathi P; Becker JE; Changela A; Chaudhary R; Cheng C; Gaudinski M; Gorman J; Harris DR; Lee M; Morano NC; Novik L; O'Dell S; Olia AS; Parchment DK; Rawi R; Roberts-Torres J; Stephens T; Tsybovsky Y; Wang D; Van Wazer DJ; Zhou T; Doria-Rose NA; Koup RA; Shapiro L; Douek DC; McDermott AB; Kwong PD
    Cell Rep; 2023 Jul; 42(7):112755. PubMed ID: 37436899
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses.
    Steichen JM; Lin YC; Havenar-Daughton C; Pecetta S; Ozorowski G; Willis JR; Toy L; Sok D; Liguori A; Kratochvil S; Torres JL; Kalyuzhniy O; Melzi E; Kulp DW; Raemisch S; Hu X; Bernard SM; Georgeson E; Phelps N; Adachi Y; Kubitz M; Landais E; Umotoy J; Robinson A; Briney B; Wilson IA; Burton DR; Ward AB; Crotty S; Batista FD; Schief WR
    Science; 2019 Dec; 366(6470):. PubMed ID: 31672916
    [TBL] [Abstract][Full Text] [Related]  

  • 80. How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?
    Klasse PJ; Sanders RW; Cerutti A; Moore JP
    AIDS Res Hum Retroviruses; 2012 Jan; 28(1):1-15. PubMed ID: 21495876
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.